<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tamsulosin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tamsulosin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tamsulosin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11070" href="/d/html/11070.html" rel="external">see "Tamsulosin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="100616" href="/d/html/100616.html" rel="external">see "Tamsulosin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F224754"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Flomax</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868330"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Tamsulosin CR;</li>
<li>Flomax CR;</li>
<li>RATIO-Tamsulosin [DSC];</li>
<li>SANDOZ Tamsulosin;</li>
<li>SANDOZ Tamsulosin CR;</li>
<li>TEVA-Tamsulosin CR;</li>
<li>TEVA-Tamsulosin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F224794"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha <sub>1</sub> Blocker</li></ul></div>
<div class="block doa drugH1Div" id="F224759"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (monotherapy or combination therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>In patients with moderate to severe predominant storage lower urinary tract symptoms, use in combination with beta-3 agonist or anticholinergic agent. In patients with a significantly enlarged prostate (prostate volume &gt;30 mL, prostate-specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam), use in combination with 5-alpha reductase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Initial and maintenance: 0.4 mg once daily. If response is inadequate after 2 to 4 weeks, may increase to 0.8 mg once daily. If therapy is discontinued or interrupted for several days, restart with 0.4 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Controlled-release tablet [Canadian product]: 0.4 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8cd9ff1-4d6f-435b-bbef-0fd178f6d5ca">Chronic prostatitis/chronic pelvic pain syndrome in males</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic prostatitis/chronic pelvic pain syndrome in males (off-label use): Oral:</b> Initial: 0.4 mg once daily for 6 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pontari.2018','lexi-content-ref-22471591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pontari.2018','lexi-content-ref-22471591'])">Ref</a></span>). If response to initial therapy is inadequate, referral to a urologist is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21205969','lexi-content-ref-23526487','lexi-content-ref-Pontari.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21205969','lexi-content-ref-23526487','lexi-content-ref-Pontari.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d44d52d2-92fa-4d24-85f2-cc1c62bfdcf7">Lower urinary tract symptoms in males</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Lower urinary tract symptoms in males (off-label use): </b>
<i>Bladder outlet obstruction and low postvoid residual:</i>
<b>Oral:</b> Initial: 0.4 mg once daily; may combine with an anticholinergic agent if symptoms of overactive bladder persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12771763','lexi-content-ref-25834406','lexi-content-ref-25070148','lexi-content-ref-23537687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12771763','lexi-content-ref-25834406','lexi-content-ref-25070148','lexi-content-ref-23537687'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="73be740a-c547-4fd4-8ae5-f791c818e17d">Ureteral stent-related urinary symptoms, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stent-related urinary symptoms, treatment (off-label use):</b>
<b>Oral:</b> 0.4 mg once daily; treatment was initiated following stent placement and duration of therapy in trials ranged from 1 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18338955','lexi-content-ref-19277623','lexi-content-ref-19641362','lexi-content-ref-21791359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18338955','lexi-content-ref-19277623','lexi-content-ref-19641362','lexi-content-ref-21791359'])">Ref</a></span>); may also be given in combination with an anticholinergic agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27809592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27809592'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f22af56-3956-4591-9dca-11295dae391d">Ureteral stone(s) expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stone(s) expulsion (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients with ureteral stones &gt;5 and ≤10 mm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-27908918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-27908918'])">Ref</a></span>). Although most evidence exists for distal ureteral stones, given the low side effect profile of alpha-blockers, may consider use in patients with stones in any location of ureter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.4 mg once daily until stone passage or for up to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193417','lexi-content-ref-20414396','lexi-content-ref-24691989','lexi-content-ref-27908918','lexi-content-ref-29137830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193417','lexi-content-ref-20414396','lexi-content-ref-24691989','lexi-content-ref-27908918','lexi-content-ref-29137830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjunctive therapy following shock wave lithotripsy to facilitate clearance of residual stones:</i>
<b>Oral:</b> 0.4 mg once daily; initiate therapy immediately after extracorporeal shock wave lithotripsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25915454','lexi-content-ref-21166579','lexi-content-ref-21802124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25915454','lexi-content-ref-21166579','lexi-content-ref-21802124'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990833"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8973992','lexi-content-ref-Miyazawa.1','lexi-content-ref-9696967','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8973992','lexi-content-ref-Miyazawa.1','lexi-content-ref-9696967','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: No dosage adjustment likely to be necessary (has not been studied); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment likely to be necessary (has not been studied); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment likely to be necessary (has not been studied); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988053"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F224760"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812556"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="100616" href="/d/html/100616.html" rel="external">see "Tamsulosin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d6b8596-fa2c-4a6d-9990-0f7ecbc39389">Primary bladder neck dysfunction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary bladder neck dysfunction:</b> Limited data available: Children ≥3 years and Adolescents: Oral: Initial dose: 0.2 mg once daily; increase by 0.2 mg increments based on response (symptoms and urodynamic studies) and tolerability. Mean effective dose: 0.4 mg daily; maximum reported daily dose: 0.8 mg/<b>day</b>. Dosing based on 2 trials evaluating treatment with alpha blockers, including over 50 pediatric patients who received tamsulosin. Treatment resulted in improved urine flow rates and decreased post-void residual urine volume; values returned to pretreatment levels when therapy was discontinued. Tamsulosin was well tolerated with no major adverse effects, and benefits continued for at least 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15592078','lexi-content-ref-20022041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15592078','lexi-content-ref-20022041'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="843e8d35-507b-4c89-905e-8ceb1ff42146">Ureteral calculi expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral calculi expulsion: </b>Limited data available; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 4 years: Oral: 0.4 mg once daily; a lower dose of 0.2 mg has also been reported; however, this dosage form may not be available in some countries including the United States and Canada (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26413330','lexi-content-ref-22099477','lexi-content-ref-24518765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26413330','lexi-content-ref-22099477','lexi-content-ref-24518765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;4 years and Adolescents: Oral: 0.4 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26413330','lexi-content-ref-22099477','lexi-content-ref-33524970','lexi-content-ref-24518765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26413330','lexi-content-ref-22099477','lexi-content-ref-33524970','lexi-content-ref-24518765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on limited prospective and retrospective trials and 2 meta-analyses that evaluated the efficacy of alpha-adrenergic blockers for facilitation of spontaneous stone passage in pediatric patients with distal urolithiasis (stones were generally ≤12 mm); compared with placebo, tamsulosin was associated with greater expulsion rate and decreased expulsion time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29859007','lexi-content-ref-35498769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29859007','lexi-content-ref-35498769'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729840"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations. Based on experience in adult patients with CrCl ≥10 mL/minute, data suggest no adjustment needed; for more severe renal impairment, use has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F52729841"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations. Based on experience in adult patients with mild to moderate hepatic impairment, data suggest no adjustment needed; for more severe hepatic impairment, use has not been studied.</p></div>
<div class="block arsc drugH1Div" id="F54862104"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Floppy iris syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraoperative floppy iris syndrome </b> has been reported in patients with current or prior use of alpha-1 blockers, particularly tamsulosin, undergoing cataract or glaucoma surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827','lexi-content-ref-18384448','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827','lexi-content-ref-18384448','lexi-content-ref-25073735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not completely established; may be related to a combination of the pharmacologic action (ie, inhibition of the iris dilator smooth muscle contraction) and long-term smooth muscle atrophy from accumulation in iris pigment epithelial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827','lexi-content-ref-16863971','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827','lexi-content-ref-16863971','lexi-content-ref-25073735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur with current (within a few weeks of initiation) or prior use (years following discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827','lexi-content-ref-25073735'])">Ref</a></span>). A minimum 3-month duration of alpha-1 blocker use has been proposed as a risk for IFIS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18388959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18388959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk highest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827','lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Male sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased pre-operative dilated pupil diameter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin is associated with <b>orthostatic hypotension</b>, which can manifest as <b>dizziness</b> and <b>vertigo</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, inhibition of vascular smooth muscle contraction and vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; “first dose” orthostatic hypotension may occur 4 to 8 hours after dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk lowest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10364649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10364649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• First dose or redose after dose interruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid increase in dose</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that cause orthostatic hypotension (eg, antihypertensives, nitrates, PDE-5 inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27551761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27551761'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F224726"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (by orthostatic testing: first dose: 6% to 7%, chronic use: 16% to 19%; symptomatic: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Tamsulosin: Adverse Reaction: Orthostatic hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">491</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Studies 1 &amp; 2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Studies 1 &amp; 2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">253</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Study 1: 4 hours after first dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">250</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Study 1: 8 hours after first dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">492</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic; Studies 1 &amp; 2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic; Studies 1 &amp; 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculation failure (8% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (9% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, headache (19% to 21%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Tamsulosin: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">492</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (13% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (8% to 9%), drowsiness (3% to 4%), insomnia (1% to 2%), vertigo (1%)<span class="lexi-table-link-container"> (<a aria-label="Vertigo table link" class="lexi-table-link" data-table-id="lexi-content-vertigo" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vertigo')">table 3</a>)</span><span class="table-link" style="display:none;">Vertigo</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vertigo" frame="border" id="lexi-content-vertigo" rules="all">
<caption style="text-align:center;">
<b>Tamsulosin: Adverse Reaction: Vertigo</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamsulosin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">492</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (3% to 5%), pharyngitis (6%), sinusitis (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (Lijnen 2003), erythema multiforme (Hu 2019), exfoliative dermatitis, fixed drug eruption (Montazer 2020), skin photosensitivity (Tan 2018), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Marconi 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Choroidal detachment (Kerimoglu 2010), intraoperative floppy iris syndrome (in patients undergoing cataract or glaucoma surgery) (Keklikci 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, epistaxis</p></div>
<div class="block coi drugH1Div" id="F224738"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, angioedema, rash, urticaria, pruritus, respiratory symptoms) to tamsulosin or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with strong CYP3A4 inhibitors (including ketoconazole)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F224723"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina: Discontinue if symptoms of angina occur or worsen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide allergy: Rarely, patients with a sulfa allergy have also developed an allergic reaction to tamsulosin; avoid use when previous reaction has been severe or life-threatening.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, tamsulosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients undergoing cataract surgery: Intraoperative floppy iris syndrome has been observed in patients undergoing cataract surgery who were on or were previously treated with alpha-1 blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. May require modifications to surgical technique; instruct patients to inform ophthalmologist of current or previous alpha-1 blocker use when considering eye surgery.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878645"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Tamsulosin has been well tolerated in pediatric patients during trials when used for management of nephrolithiasis and primary bladder neck dysfunction (Donohoe 2005; Mokhless 2012; Tasian 2014; Van Batavia 2010). Studies using tamsulosin for the management of elevated detrusor leak point pressure in pediatric patients (ages 2 to 16 years) with a known neurological disorder (eg, spina bifida) failed to show efficacy.</p></div>
<div class="block foc drugH1Div" id="F224732"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flomax: 0.4 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg</p></div>
<div class="block geq drugH1Div" id="F224719"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F224739"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Flomax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg (per each): $11.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tamsulosin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg (per each): $0.53 - $4.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868331"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flomax CR: 0.4 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg</p></div>
<div class="block adm drugH1Div" id="F224735"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer capsules ~30 minutes after the same mealtime each day. Per the manufacturer’s labeling, capsules should be swallowed whole; do not crush, chew, or open. In pediatric trials, capsules were opened and the contents mixed with food (eg, yogurt or pudding) or juice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15592078','lexi-content-ref-24518765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15592078','lexi-content-ref-24518765'])">Ref</a></span>); however, if administered via this method, do not crush, chew, or dissolve the granules as this may lead to rapid release and increased risk of adverse effects (manufacturer data on file). Administration via nasogastric, gastric, jejunostomy, or other feeding tubes has not been adequately evaluated, and based on limited reports, the granules may adhere to the tube with resultant blockage (manufacturer data on file). The controlled-release tablet [Canadian product] should be administered at the same time each day with or without food, and should be swallowed whole.</p></div>
<div class="block admp drugH1Div" id="F52613897"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Per the manufacturer, capsules should be swallowed whole; do not crush, chew, or open. In pediatric trials, capsules were opened and the contents mixed with food (eg, yogurt, pudding), water, or juice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15592078','lexi-content-ref-22099477','lexi-content-ref-33524970','lexi-content-ref-24518765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15592078','lexi-content-ref-22099477','lexi-content-ref-33524970','lexi-content-ref-24518765'])">Ref</a></span>); however, if administered via this method, do not crush, chew, or dissolve the granules as this may lead to rapid release and increased risk of adverse effects (manufacturer data on file). Administration via nasogastric, gastric, jejunostomy, or other feeding tubes has not been adequately evaluated, and based on limited reports, the granules may adhere to the tube with resultant blockage (manufacturer data on file).</p></div>
<div class="block use drugH1Div" id="F224734"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia:</b> Treatment of signs and symptoms of benign prostatic hyperplasia (BPH)</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for the treatment of hypertension.</p></div>
<div class="block off-label drugH1Div" id="F25744917"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic prostatitis/chronic pelvic pain syndrome in males; Lower urinary tract symptoms in males; Ureteral stone(s), expulsion; Ureteral stent-related urinary symptoms, treatment</p></div>
<div class="block mst drugH1Div" id="F224801"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flomax may be confused with Flonase, Flovent, Foltx, Fosamax</p>
<p style="text-indent:-2em;margin-left:4em;">Tamsulosin may be confused with tacrolimus, tamoxifen, terazosin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flomax [US, Canada, and multiple international markets] may be confused with Flomox brand name for cefcapene [Japan]; Volmax brand name for salbutamol [multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Flomax: Brand name for tamsulosin [US, Canada, and multiple international markets], but also the brand name for morniflumate [Italy]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F224788"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F224728"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Alpha1-Blockers (Uroselective) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F224751"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Capsules: Fasting increases bioavailability by 30% and peak concentration 40% to 70%. Management: Administer 30 minutes after the same meal each day. <b>Note:</b> The controlled-release tablet formulation [Canadian product] is not affected by food and can be taken with or without food at the same time each day.</p></div>
<div class="block rep_considerations drugH1Div" id="F55434115"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Ejaculation failure, ejaculation disorder, retrograde ejaculation, and decreased ejaculation has been associated with use of tamsulosin.</p></div>
<div class="block pri drugH1Div" id="F224740"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of tamsulosin for ureteral calculi expulsion in pregnancy is limited (Bailey 2016; Theriault 2020). Other treatments such as stents or ureteroscopy, are currently recommended if stone removal is needed (AUA/ES [Assimos 2016]; EAU [Türk 2019]; Lloyd 2016).</p></div>
<div class="block brc drugH1Div" id="F55434116"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if tamsulosin is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F25803358"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">International Prostate Symptom Score (baseline and 4 to 12 weeks after treatment initiation); urinalysis (baseline); BP; prostate cancer screening prior to initiation and then as directed; mental alertness; objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021]; manufacturer’s labeling).</p></div>
<div class="block pha drugH1Div" id="F224722"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tamsulosin is an antagonist of alpha<sub>1A</sub>-adrenoreceptors in the prostate. Smooth muscle tone in the prostate is mediated by alpha<sub>1A</sub>-adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha<sub>1</sub>-receptors in the prostate are of the alpha<sub>1A</sub> subtype.</p></div>
<div class="block phk drugH1Div" id="F224737"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetics in pediatric patients (ages 2 to 16 years) were found to be similar to adult values (Tsuda 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: &gt;90%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 16 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94% to 99%, primarily to alpha-1 acid glycoprotein (AAG)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive) via CYP3A4 and 2D6; metabolites undergo extensive conjugation to glucuronide or sulfate</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Fasting: 30% increase</p>
<p style="text-indent:-2em;margin-left:2em;">Steady-state: By the fifth day of once-daily dosing</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy volunteers: 9 to 13 hours; Target population: 14 to 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Fasting: 4 to 5 hours; With food: 6 to 7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (76%, &lt;10% as unchanged drug); feces (21%)</p></div>
<div class="block phksp drugH1Div" id="F51221491"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC is 40% higher in subjects 55 to 75 years of age compared with subjects 20 to 32 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F224742"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gamcet | Od tam | Omnic | Omnic ocas | Prosta Tab | Prostulosin | Tamictor | Tamsumac | Urimax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aclosan | Biprokam | Controlpros | Denverprost | Diufortan | Espontal | Flocprox | Lostam | Omnic | Prostoklar | Reduprost | Secotex | Sulos | Tamsulosina Richet | Tamsulosina teva | Tamsuna | Tansiloprost | Tarusol | Toloxane | Travelgum | Uralos | Uriflux | Urocetina | Uroprost Q</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aglandin | Alna | Omix | Tamsulosin +Pharma | Tamsulosin 1a pharma | Tamsulosin actavis | Tamsulosin Easypharm | Tamsulosin genericon | Tamsulosin Hexal | Tamsulosin Interpharm | Tamsulosin krka | Tamsulosin ratiopharm | Tamsulosin sandoz | Tamsulosin stada | Tamsulosin-Arcana | Tamsunova</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo tamsulosin sr | Flomax | Flomaxtra | Flosix | Tamsulosin sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Eziflo | Ezipas | Flonor | Hi flow | Maxrin | Mictrol | Prostacin | Prostanil | Sasolin | Tamcontin | Tamfast | Tamlosin | Tamsin | Tamsol | Tamsule | Uricare | Urinom | Urocap | Uroflo | Urolosin | Uromax | Uropass | Urotam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Omic | Tamsulos Aes | Tamsulosine Docpharma | Tamsulosine eg | Tamsulosine hcl krka | Tamsulosine Merck | Tamsulosine Ratiopharm | Tamsulosine sandoz | Tamsulosine Teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fokusin | Fokusin sr | Omnic | Omnic tocas | Tamaliz | Tamsol | Tamsucon | Tamsudil | Tanyz | Urimax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de tansulosina | Contiflo | Omnic | Omnic ocas | Rettan | Secotex | Secotex Adv | Stub | Tamsulon | Tansudart | Tasulil | Usoleg</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Omix | Pradif | Tamsulosin | Tamsulosin actavis | Tamsulosin axapharm | Tamsulosin Helvepharm | Tamsulosin Mepha | Tamsulosin mylan | Tamsulosin retard zentiva | Tamsulosin sandoz | Tamsulosin sandoz eco | Tamsulosin Spirig | Tamsulosin spirig hc | Tamsulosin Streuli | Tamsulosin T | Tamsulosin t helvepharm | Tamsulosin t mepha | Tamsulosin t spirig hc | Tamsulosin teva | Tamsunax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eupen | Gotely | Nefex | Omnic | Prostall | Secotex | Secotex ocas | Singotex | Sulix | Tamsol | Tamsulosina | Vi Uril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bi tan | Harnal | Ji da ben te | Ji suo | Qi suo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Demulin er | Od tam | Omnic | Omnic ocas | Proslosin | Secotex | Secotex ocas | Sulosin | Tamsecox | Tamsulon | Tamsulosin | Tamsulosina | Tamsulosina clorhidrato | Tamsulosina sandoz | Tamsumax | Valudar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Tamis | Fokusin | Lannatam | Omnic | Omnic tocas | Taflosin | Tamipro | Tamsulonorm | Tamsulosin +Pharma | Tamsulosin aurovitas | Tamsulosin hcl Sandoz | Tamsulosin hcl teva | Tamurox | Tanyz eras</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alna | Alna Ocas | Omnic | Omsula | Prostacure | Prostadil | Prostalitan | Tadin | Tamsu astellas | Tamsu-Q | Tamsublock | Tamsulo-Isis | Tamsulosin 1a pharma | Tamsulosin AbZ | Tamsulosin AL | Tamsulosin aristo | Tamsulosin Aurobindo | Tamsulosin basics | Tamsulosin basics sun | Tamsulosin beta | Tamsulosin Biomo | Tamsulosin CT | Tamsulosin Hexal | Tamsulosin ratiopharm | Tamsulosin sandoz | Tamsulosin stada | Tamsulosin Winthrop | Tamsulosin zentiva | Tamsulosinhydrochlorid actavis | Tamsulosinhydrochlorid Awd | Tamsulosinhydrochlorid Heumann | Tamsumedin | Tamsunar</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Cepalux | Masulin | Omnistad | Tamsin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Espontal | Fulmen | Gaflox | Normacid | Prosina | Prostamida | Prostoklar | Protober | Secotex | Secotex ocas | Soluprost | Tamsul | Tamsulon | Tamsulosina | Tamsulosina ethical | Tamsulosina hcl | Taven | Urisan | Veltam</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amsulona | Contiflo | Eupen | Hiprostam | Lostam | Oxialprost | Prostall | Prostoklar | Secotex | Tamsina | Tamsulon | Tamsulosina | Tamsulosina nifa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flosin | Fokusin | Omnic | Omnic tocas | Omsal | Tamsulosin auxilia | Tamsulosin lannacher | Tamsulosin sandoz | Tamsulosin stada | Tanyz | Tanyz eras | Urostad</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Block alpha | Cure pro | Curepro xr | Firamazin | Kemprost | Kemprost sr | Losiprost | Normirama | Omnic | Tamic | Tamsul | Tamsulin | Tamsulosin | Tamsunorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Inreq | Omnic ocas | Sebrane | Sebrane neo | Tamsulosina almus | Tamsulosina Alter | Tamsulosina Apotex | Tamsulosina Aurobindo | Tamsulosina Cinfa | Tamsulosina combix | Tamsulosina Cuve | Tamsulosina Davur | Tamsulosina Inibsa | Tamsulosina Kern Pharma | Tamsulosina krka | Tamsulosina Mabo | Tamsulosina Mylan Pharmaceuticals | Tamsulosina Normon | Tamsulosina Pensa | Tamsulosina Pharmagenus | Tamsulosina Qualigen | Tamsulosina Ratiopharm | Tamsulosina sandoz | Tamsulosina Stada | Tamsulosina Tarbis | Tamsulosina Tecnigen | Tamsulosina teva | Tamsulosina vir | Tamsulosina Winthrop | Tamsulosina zentiva | Urolosin | Urolosin ocas | Zuantrip</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Od tam</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Expros | Omnic | Omnic ocas | Promictan | Tamictor | Tamsact | Tamsu-Anlini | Tamsucinfa | Tamsufarm | Tamsugaran | Tamsulosiinihydrokloridi arrow | Tamsulosiinihydrokloridi Krka | Tamsulosiinihydrokloridi Orion | Tamsulosiinihydrokloridi Sandoz | Tamsumin | Tamsupli</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Josir | Mecir | Omexel | Omix | Tamsulosine | Tamsulosine actavis | Tamsulosine Almus | Tamsulosine Arrow | Tamsulosine Biogaran | Tamsulosine eg | Tamsulosine evolugen | Tamsulosine isomed | Tamsulosine krka LP | Tamsulosine Mylan | Tamsulosine ranbaxy | Tamsulosine sandoz | Tamsulosine Teva | Tamsulosine Winthrop | Tamsulosine zentiva | Tamsulosine zydus france</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alphacard | Contiflo | Diffundox | Faramsil | Flectone | Flomax | Flomax Relief | Flomax relief mr | Flomaxtra xl | Galebon | Losinate | Losinate mr | Omsula | Pamsvax | Pamsvax Almus | Petyme | Pinexel | Prosurin | Stronazon | Tabphyn MR | Tamfrex xl | Tamsaprost | Tamsulosin | Tamsulosin Almus | Tamsumac | Tamurex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Novelio | Omnic | Pradif | Prosolvin | Ranomax | Sintamel | Tamsol | Tamsolet | Tamsulijn | Tamsulosin/ariti | Tamsulosin/Generics | Tamsulosin/mylan | Zidrolin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo tamsulosin | Harnal | Harnal ocas | Maxrin | Tamsulosin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bazetham | Flosin | Modiar | Omnic | Omnic ocas | Tamaliz | Tamosin | Tamsich | Tamsu | Tamsulozin PharmaS | Tanyz | Tanyz eras | Urimax</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Flosin | Omipro | Omnic | Omnic tocas | Prosolin | Provosal | Tamsulonorm | Tamsulosin | Tamsulosin Pharmacenter | Tanyz eras | Totalprost | Uro tam</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Harnal | Tamsulosin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kirnom XL | Omnexel | Omnic | Omsil | Prolosin | Tamnexyl | Tamnic | Tamsu | Tamsulosin | Tamzeltos | Tanyz</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Omnic | Promnix | Tamsulin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aivo | Alfatam | Bezip | Consistam | Contiflo | Dynapres | Flokind | Flomax | Fulflow | Geritam | Jyotam | Protam | Reflow | Tamby | Tamcuf | Tamdosin | Tamflo | Tamgress | Tamlocept | Tamlosig | Tampres | Tamsin | Tamstream | Tamsufine | Tamsuhenz | Tamsukem | Tamsulin | Tasulin | Temsujohn | Urigrip | Urimax | Urinat | Urinice | Uripro | Urisurge | Uritin | Uronex | Veltam</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Antunes | Botam | Lura | Omnic | Pradif | Tamsulosina | Tamsulosina Acv | Tamsulosina almus | Tamsulosina arrow | Tamsulosina Aurobindo | Tamsulosina Fg | Tamsulosina fidia | Tamsulosina krka | Tamsulosina sandoz | Uromen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Eziflo | Omnic | Omnic ocas | Prostanic | Tamsin | Uriflo</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Halonerol | Halthrow | Haranasin | Harleave | Harnal | Harnnat | Hartam | Palnac | Restream | Tamslon | Tamsulosin HCL | Tamsulosin Hcl Kowa | Tamsulosin Hcl Ohara | Tamsulosin Hcl Taisho | Tamsulosin Hcl Takata | Urosulol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Contiflo od | Eziflo | Flomax | Flosure | Maxflow | Plastum | Prostaflo od | Tamcontin | Tamsolin | Tamsumac | Tamzed | Weltam xl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arlunal sr | Bearosin | Bearosin sr | Binex tamsrosin hcl | Binex tamsrosin hcl er | Boryung tamsulosin hcl | Boryung tamsulosin hcl sr | C trocin sr | Citrosin sr | Dongkwang tamsulosin sr | Dongsung tamsulosin | Genilosin | Habi sr | Hanall tamsulosin | Hanmi tams | Harlosin D | Harlosin sr | Harnal | Harnal d | Haru d sr | Harucare | Harucin sr | Harucure | Harucure sr | Harulon sr | Harutam | Harutam sr | Hyundai tamsulosin hcl | Inist tamsulosin | Inist tamsulosin sr | K tams sr | Lutsnal | Neolosin | Neorocin | Neorosin | Pharma tamsulosin | Pratam sr | Qminal | Qminal sr | Samsung tamsulosin sr | Scarocin | Silontam sr | Siwonal | Siwonal sr | Sulosin | Sulosin D | Tamilosin SR | Taminal | Tamlos | Tamlosin | Tamlosin sr | Tamlostar | Tamlostar sr | Tamlusin | Tamlusin d sr | Tamlusindi sr | Tampasin sr | Tampilon | Tams | Tamscare | Tamsdol | Tamsen | Tamsen sr | Tamsil sr | Tamsilo SR | Tamsin | Tamsin sr | Tamslen sr | Tamslo | Tamslon sr | Tamslusin | Tamsmin | Tamsnal | Tamsnal sr | Tamsol | Tamsol sr | Tamsonal | Tamsosin | Tamsosin sr | Tamspeed | Tamspin | Tamspla | Tamspon | Tamspro sr | Tamsro | Tamsrosin hcl | Tamsta | Tamstar SR | Tamsthroa | Tamstro | Tamstro SR | Tamsudol SR | Tamsul m | Tamsul m sr | Tamsul sr | Tamsulo | Tamsulogen sr | Tamsuloisin | Tamsulol er | Tamsulon | Tamsulonal sr | Tamsulosin | Tamsulosin sr | Tamsunal | Tamsuro sr | Tamsuron | Tamsurosin sr | Tamswel | Tamszin sr | Tamulon | Tamulosin | Tamunal | Tarosin sr | Tarunal | Time s | Timeal | Tipilosin | Unilosin | Urinstar sr | Uronal | Uropa sr | Urotams sr | Utanal | Utanal sr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eziflo | Omnic | Prosta Tab PR | Tamsulin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo tamsulosin | Omnic | Pinexel pr | Prostafine | Talusin | Tamsulin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Flosin | Fokusin | Omnic | Omsal | Ranomax | Tamsulosin lannacher | Tamsulosin stada | Tanyz eras | Urostad</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Doctamsulosine | Omic | Ranomax | Tamsulosin Hexal | Tamsulosin ratiopharm | Tamsulosine eg | Tamsulosine hydrochloride yamanouchi pharma</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Omnic | Omsal | Ranomax | Tamipro | Tamosin | Tamsulosin | Tamsulosin norameda | Tamsulosin stada | Tanyz eras | Urostad</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Contiflo | Tamsulosine win | Umax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alfatam | Alphalock | Amzuvag | Asoflon | Delitam | Dronelyn tec | Fedpros | Flucisten | Grandlord | Hipebe | Jumslim | Kresulix | Nondecel | Ormusul | Perplax | Prerikusine | Secadryckel | Secotex | Secotex ocas | Sedoty | Suprosina | Tamablan | Tamablan pf | Tamsulosina | Tatsocap | Texulon | Uprosol | Weltam | Zulotam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Harnal | Tamsin forte</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Contiflo od | Flowel | Glomaxtra xl | Hansulosin | Lifeback tamsulosin | Norlosin xl | Tamsulosin | Tamsumac</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mapelor ocas | Omnic | Tamsulosin | Tamsulosine genthon | Tamsulosine HCl A | Tamsulosine Hcl Actavis | Tamsulosine HCl Aurobindo | Tamsulosine Hcl CF | Tamsulosine hcl merck | Tamsulosine HCl Mylan | Tamsulosine hcl ratiopharm | Tamsulosine hcl retard teva | Tamsulosine hcl sandoz | Tamsulosine hcl sun | Tamsulosine hydrochloride Genthon | Tamsulosine Mylan | Tamsulosine sandoz | Tamsulosinehydrochloride PCH</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cepalux | Miktosan | Omnic | Tamsulosin | Tamsulosin arrow | Tamsulosin Hexal | Tamsulosin mylan | Tamsulosin ratiopharm | Tamsulosin teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Flomax | Tamsulosin Rex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Adeprost | Aliner s | Amsulona | Ditamsuloss | Ecksulona | Glancin | Maxflo | Omnic | Oriflow | Prostadel | Secotex | Secotex ocas | Tamsul | Tamsulip | Tamsulofar | Tamsulon | Tamsulosina | Tamsulosina clorhidrato | Tamta | Uriglob | Veltam</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alfatam | Amso | Harnal | Pimax | Prostalife | Prostazin | Prozelax | Proztab ER | Sulopros | Sultam | Tamsia | Tamsilon | Tamsolin | Tamsul | Tamsulon xl | Tamsulosin | Tamsumax | Tamzor | Tamzu | Urilax | Urimax | Uritam | Urolosin | Urotosin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alfamax | Alfatam | Alfawrd sr | Colspa | Contiflo | Dribble sr | Ezurin | Flomex | Flonorm | Flosure | Flowmax | Flowset sr | Lamt | M sol | Maxflow | Maxron | Maxsure | Maylan | Medsolin | Proset | Prostam | Prostop | Prostreat | Saiflow | Solosin sr | Sulo | T sin | Talosin | Talsin | Tamcap | Tamcin | Tamiso mr | Tamlin mr | Tamline | Tampro | Tams g | Tamsar | Tamsol | Tamsolin | Tamsugene sr | Tamsulis | Tamsuna | Tasipan | Tasoline | Tasudil | Telosin | Temgal | Teslosin sr | Timsol | Tosson | Tulosin mr | Uratim | Uricare | Uriflow | Urimax | Uripro | Uritreat | Urivent | Urosul</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adatam | Adatam XR | Apo Tamis | Bazetham | Fokusin | Omnic | Omsal | Prostamnic | Proximic | Ranlosin | Symlosin | Tamiron | Tamispras | Tamoptim | Tamsiger | Tamsudil | Tamsugen | Tamsulek | Tamsulosin Genoptim | Tamsunorm | Tanyz eras | Uprox | Uprox xr | Urostad</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Flomax | Tamsulosin | Tamsulosin HCL | Tamsulosin hydrchloride</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Magrir | Omnic | Pradif | Sebrane xr | Tansulosina | Tansulosina Aurobindo | Tansulosina germed | Tansulosina Krka | Tansulosina Labesfal | Tansulosina Sandoz | Tansulosina Zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Androsist | Eupen | Ferona | Lostam | Nasul | Prostar | Secotex ocas | Tamsucar | Tamsulon | Tamsulosina celsius | Tamsulosina hcl | Tamsulosina imedic | Tamsulosina lp prosalud | Tamsulosina sandoz | Tamsulosina savant pharm | Torpas | Urotic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Contiflo OD | EZIFLO-UPM | Flomax | Gamcet | Omnic Ocas | Prosta-Tab PR | Tamsolin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Contiflo mr | Fokusin | Omnic tocas | Seldono | Tamsol | Tanyz</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fokusin | Glancin | Glansin | Hyperprost | Mictosin | Omnic | Omnic ocas | Omsulosin | Proflosin | Revokarin | Sonizin | Tamsulon | Tamsulon fs | Tamsulosin | Tamsulosin bacter | Tamsulosin binergia | Tamsulosin canon | Tamsulosin obl | Tamsulosin roslex | Tamsulosin teva | Tamzelin | Tanyz eras | Tanyz K | Tulosin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cigapro | Gamcet | Harnal | Omnic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tamicten</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Harnal | Harnal ocas | Tasulose</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bazetham | Miktan | Omnic | Taflosin | Tamlos | Tamsulozin mylan | Tanyz | Tanyz eras</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Flosin | Fokusin | Geroprostan | Omipro | Omnic | Solesmin | Tamsulosin +Pharma | Tamsulosin Merck | Tamsulosin Pharmacenter | Tamsulosin teva | Tamsulozin | Tanyz | Tanyz eras | Urostad | Urotam</span>;</li>
<li>
<span class="countryCode">(SY)</span> <span class="country">Syrian Arab Republic</span><span class="countrySeparator">: </span><span class="drugName">Omixase</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Harnal | Uroflow</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Josir | Mecir | Omix | Omnic ocas | Prostam</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Flomax | Floprost MR | Tamidra | Tocas | Uromax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alfatam | Elegant | Harnalidge | Harnalidge ocas | Holigin | Maxflow | Tamlosin | Tamlosin d | Tamokas | Tamso | Tamsulosin | Urnal | Zotan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adenorm | Alfatam | Basetam | Flosin | Fokusin | Omlos | Omnic | Omniprost | Tamsin forte | Tanyz | Urimak | Urofrin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Tamcontin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Prostam | Prostoklar | Secoprost | Secotex | Urolosin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sasolin mr | Secotex | Secotex ocas | Sulix | Sulixtra | Tamostin | Tamsulon | Tamsulosina | Tamsulosina clorhidrato | Tamsupros | Tamsuwell | Tansulosina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Floezy | Xalgetz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Beniprosin | Flomax | Omsal | Pravlex | Prostaflo | Uromax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Contiflo | Urimax</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Contiflo od</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19077827">
<a name="19077827"></a>Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. <i>Curr Opin Ophthalmol</i>. 2009;20(1):37-41. doi:10.1097/ICU.0b013e32831bc0ad<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/19077827/pubmed" id="19077827" target="_blank">19077827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193417">
<a name="19193417"></a>Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. <i>Urology</i>. 2009;73(4):706-709. doi:10.1016/j.urology.2008.11.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/19193417/pubmed" id="19193417" target="_blank">19193417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20414396">
<a name="20414396"></a>Ahmed AF, Al-Sayed AY. Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: Prospective, randomized, comparative study. <i>Korean J Urol</i>. 2010;51(3):193-197. doi:10.4111/kju.2010.51.3.193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/20414396/pubmed" id="20414396" target="_blank">20414396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26413330">
<a name="26413330"></a>Aldaqadossi HA, Shaker H, Saifelnasr M, Gaber M. Efficacy and safety of tamsulosin as a medical expulsive therapy for stones in children. <i>Arab J Urol</i>. 2015;13(2):107-111. doi:10.1016/j.aju.2015.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/26413330/pubmed" id="26413330" target="_blank">26413330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21205969">
<a name="21205969"></a>Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. <i>JAMA</i>. 2011;305(1):78-86. doi:10.1001/jama.2010.1913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/21205969/pubmed" id="21205969" target="_blank">21205969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27238616">
<a name="27238616"></a>Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society Guideline, PART I. <i>J Urol.</i> 2016;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/27238616/pubmed" id="27238616" target="_blank">27238616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771763">
<a name="12771763"></a>Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. <i>J Urol</i>. 2003;169(6):2253-2256. doi:10.1097/01.ju.0000067541.73285.eb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/12771763/pubmed" id="12771763" target="_blank">12771763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26144335">
<a name="26144335"></a>Bailey G, Vaughan L, Rose C, et al. Perinatal outcomes with tamsulosin therapy for symptomatic urolithiasis.<i> J Urol</i>. 2016;195(1):99-103. doi:10.1016/j.juro.2015.06.097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/26144335/pubmed" id="26144335" target="_blank">26144335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29859007">
<a name="29859007"></a>Barreto L, Jung JH, Abdelrahim A, Ahmed M, Dawkins GPC, Kazmierski M. Medical and surgical interventions for the treatment of urinary stones in children. <i>Cochrane Database Syst Rev</i>. 2018;6(6):CD010784. doi:10.1002/14651858.CD010784.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/29859007/pubmed" id="29859007" target="_blank">29859007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24691989">
<a name="24691989"></a>Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. <i>Cochrane Database Syst Rev</i>. 2014;(4):CD008509. doi:10.1002/14651858.CD008509.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/24691989/pubmed" id="24691989" target="_blank">24691989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620795">
<a name="29620795"></a>Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. <i>Cochrane Database Syst Rev</i>. 2018;4:CD008509. doi:10.1002/14651858.CD008509.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/29620795/pubmed" id="29620795" target="_blank">29620795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25915454">
<a name="25915454"></a>Chen K, Mi H, Xu G, et al. The efficacy and safety of tamsulosin combined with extracorporeal shockwave lithotripsy for urolithiasis: A systematic review and meta-analysis of randomized controlled trials. <i>J Endourol</i>. 2015;29(10):1166-1176. doi:10.1089/end.2015.0098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/25915454/pubmed" id="25915454" target="_blank">25915454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16863971">
<a name="16863971"></a>Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. <i>J Cataract Refract Surg</i>. 2006;32(8):1336-1339. doi:10.1016/j.jcrs.2006.03.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/16863971/pubmed" id="16863971" target="_blank">16863971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109982">
<a name="32109982"></a>Christou CD, Tsinopoulos I, Ziakas N, Tzamalis A. Intraoperative floppy iris syndrome: updated perspectives. <i>Clin Ophthalmol</i>. 2020;14:463-471. doi:10.2147/OPTH.S221094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/32109982/pubmed" id="32109982" target="_blank">32109982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18338955">
<a name="18338955"></a>Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. <i>J Endourol</i>. 2008;22(4):651-656. doi:10.1089/end.2007.0257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/18338955/pubmed" id="18338955" target="_blank">18338955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27809592">
<a name="27809592"></a>Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA. Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: A randomized controlled study. <i>J Endourol</i>. 2017;31(1):100-109. doi: 10.1089/end.2016.0663<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/27809592/pubmed" id="27809592" target="_blank">27809592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25834406">
<a name="25834406"></a>Dimitropoulos K, Gravas S. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>Drug Des Devel Ther</i>. 2015;9:1707-1716. doi:10.2147/DDDT.S53184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/25834406/pubmed" id="25834406" target="_blank">25834406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10364649">
<a name="10364649"></a>Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. <i>Eur Urol</i>. 1999;36(1):1-13. doi:10.1159/000019919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/10364649/pubmed" id="10364649" target="_blank">10364649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15592078">
<a name="15592078"></a>Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. <i>J Urol</i>. 2005;173(1):212-216. doi:10.1097/01.ju.0000135735.49099.8c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/15592078/pubmed" id="15592078" target="_blank">15592078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070148">
<a name="25070148"></a>Drake MJ, Chapple C, Sokol R, et al; NEPTUNE Study Group. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. <i>Eur Urol</i>. 2015;67(2):262-270. doi:10.1016/j.eururo.2014.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/25070148/pubmed" id="25070148" target="_blank">25070148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21166579">
<a name="21166579"></a>Falahatkar S, Khosropanah I, Vajary AD, Bateni ZH, Khosropanah D, Allahkhah A. Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi? <i>J Endourol</i>. 2011;25(3):495-498. doi:10.1089/end.2010.0439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/21166579/pubmed" id="21166579" target="_blank">21166579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278872">
<a name="23278872"></a>Fan B, Yang D, Wang J, et al. Can tamsulosin facilitate expulsion of ureteral stones? A meta-analysis of randomized controlled trials. <i>Int J Urol</i>. 2013;20(8):818-830. doi:10.1111/iju.12048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/23278872/pubmed" id="23278872" target="_blank">23278872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flomax.2019.01">
<a name="Flomax.2019.01"></a>Flomax (tamsulosin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FlomaxCR.2019.08">
<a name="FlomaxCR.2019.08"></a>Flomax CR (tamsulosin) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26194935">
<a name="26194935"></a>Furyk JS, Chu K, Banks C, et al. Distal ureteric stones and tamsulosin: A double-blind, placebo-controlled, randomized, multicenter trial. <i>Ann Emerg Med</i>. 2016;67(1):86-95.e2. doi:10.1016/j.annemergmed.2015.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/26194935/pubmed" id="26194935" target="_blank">26194935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27908918">
<a name="27908918"></a>Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. <i>BMJ</i>. 2016;355:i6112. doi:10.1136/bmj.i6112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/27908918/pubmed" id="27908918" target="_blank">27908918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31513023">
<a name="31513023"></a>Hu L, Dong J, Zhang S. Tamsulosin-Associated Erythema Multiforme-Like Eruption. <i>Am J Ther</i>. 2019 Aug 16. doi:10.1097/MJT.0000000000001059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/31513023/pubmed" id="31513023" target="_blank">31513023</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  JAMP Tamsulosin (tamsulosin) [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18384448">
<a name="18384448"></a>Keklikci U, Isen K, Unlu K, Celik Y, Karahan M. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. <i>Acta Ophthalmol</i>. 2009;87(3):306-309. doi:10.1111/j.1755-3768.2008.01246.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/18384448/pubmed" id="18384448" target="_blank">18384448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19302075">
<a name="19302075"></a>Kerimoglu H, Zengin N, Ozturk B, Gunduz K. Unilateral chemosis, acute onset myopia and choroidal detachment following the use of tamsulosin. <i>Acta Ophthalmol</i>. 2010;88(2):e20-e21. doi:10.1111/j.1755-3768.2008.01503.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/19302075/pubmed" id="19302075" target="_blank">19302075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8973992">
<a name="8973992"></a>Koiso K, Akaza H, Kikuchi K, et al. Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. <i>J Clin Pharmacol</i>. 1996;36(11):1029-1038. doi:10.1177/009127009603601107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/8973992/pubmed" id="8973992" target="_blank">8973992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. <i>J Urol.</i> 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14641131">
<a name="14641131"></a>Lijnen RL, de Graaf L. Systemic contact dermatitis from tamsulosin. <i>Contact Dermatitis</i>. 2003;49(1):50-51. doi:10.1111/j.0105-1873.2003.0120k.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/14641131/pubmed" id="14641131" target="_blank">14641131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26482104">
<a name="26482104"></a>Lloyd GL, Lim A, Hamoui N, et al. The use of medical expulsive therapy during pregnancy: a worldwide perspective among experts. <i>J Endourol.</i> 2016;30(3):354-358. doi:10.1089/end.2015.0587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/26482104/pubmed" id="26482104" target="_blank">26482104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577106">
<a name="31577106"></a>Marconi M, Pavez P, San Francisco I, Narvaez P. Priapism induced by use of tamsulosin: A case report and review of the literature. <i>Arch Ital Urol Androl</i>. 2019;91(3). doi:10.4081/aiua.2019.3.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/31577106/pubmed" id="31577106" target="_blank">31577106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miyazawa.1">
<a name="Miyazawa.1"></a>Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. <i>Current Therapeutic Research</i>. 2001;62(9):603-621. doi:10.1016/S0011-393X(01)80067-9</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099477">
<a name="22099477"></a>Mokhless I, Zahran AR, Youssif M, Fahmy A. Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study. <i>J Pediatr Urol</i>. 2012;8(5):544-548. doi:10.1016/j.jpurol.2011.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/22099477/pubmed" id="22099477" target="_blank">22099477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31541583">
<a name="31541583"></a>Montazer F, Jahani Amiri K, Mofarrah R, Ahmadi A, Nouripour B, Mofarrah R. A first case of fixed drug eruption due to tamsulosin. <i>J Cosmet Dermatol</i>. 2020;19(5):1143-1145. doi:10.1111/jocd.13125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/31541583/pubmed" id="31541583" target="_blank">31541583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23526487">
<a name="23526487"></a>Nickel JC, Touma N. α-Blockers for the treatment of chronic prostatitis/chronic pelvic pain syndrome: An update on current clinical evidence. <i>Rev Urol</i>. 2012;14(3-4):56-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/23526487/pubmed" id="23526487" target="_blank">23526487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25073735">
<a name="25073735"></a>Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opin Drug Saf</i>. 2014;13(9):1187-1197. doi:10.1517/14740338.2014.936376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/25073735/pubmed" id="25073735" target="_blank">25073735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551761">
<a name="27551761"></a>Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. <i>Biomed Pharmacother</i>. 2016;83:1141-1145. doi:10.1016/j.biopha.2016.08.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/27551761/pubmed" id="27551761" target="_blank">27551761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pontari.2018">
<a name="Pontari.2018"></a>Pontari, M. Chronic prostatitis and chronic pelvic pain syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17993340">
<a name="17993340"></a>Preminger GM, Tiselius HG, Assimos DG, et al; EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. <i>J Urol</i>. 2007;178(6):2418-2434. doi: 10.1016/j.juro.2007.09.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/17993340/pubmed" id="17993340" target="_blank">17993340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22712147">
<a name="22712147"></a>Ramsey E, Ramsey BL 3rd, Childers J. Floppy iris syndrome: a drug-related complication of cataract surgery. <i>JAAPA</i>. 2012;25(5):37-38, 41. doi:10.1097/01720610-201205000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/22712147/pubmed" id="22712147" target="_blank">22712147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10523895">
<a name="10523895"></a>Schulman C. Hypertrophie bénigne de la prostate: quel traitement, pour qui? [Benign hypertrophy of the prostate: which treatment, for whom?] [in French]. <i>Rev Med Brux</i>. 1999;20(4):A212-A218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/10523895/pubmed" id="10523895" target="_blank">10523895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18388959">
<a name="18388959"></a>Shah N, Tendulkar M, Brown R. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin? <i>Eye (Lond)</i>. 2009;23(3):740. doi:10.1038/eye.2008.95<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/18388959/pubmed" id="18388959" target="_blank">18388959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33524970">
<a name="33524970"></a>Soliman MG, El-Gamal O, El-Gamal S, Abdel Raheem A, Abou-Ramadan A, El-Abd A. Silodosin versus tamsulosin as medical expulsive therapy for children with lower-third ureteric stones: prospective randomized placebo-controlled study. <i>Urol Int</i>. 2021;105(7-8):568-573. doi:10.1159/000513074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/33524970/pubmed" id="33524970" target="_blank">33524970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35498769">
<a name="35498769"></a>Sun F, Bao X, Cheng D, et al. Meta-analysis of the safety and efficacy of α-adrenergic blockers for pediatric urolithiasis in the distal ureter. <i>Front Pediatr</i>. 2022;10:809914. doi:10.3389/fped.2022.809914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/35498769/pubmed" id="35498769" target="_blank">35498769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29974124">
<a name="29974124"></a>Tan CK, Yap KB. Tamsulosin-induced photosensitivity rash. <i>Singapore Med J</i>. 2018;59(6):336-337. doi:10.11622/smedj.2018072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/29974124/pubmed" id="29974124" target="_blank">29974124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23177637">
<a name="23177637"></a>Tan YK, Cha DY, and Gupta M, "Management of Stones in Abnormal Situations," <i>Urol Clin North Am</i>, 2013, 40(1):79-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/23177637/pubmed" id="23177637" target="_blank">23177637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24518765">
<a name="24518765"></a>Tasian GE, Cost NG, Granberg CF, et al. Tamsulosin and spontaneous passage of ureteral stones in children: a multi-institutional cohort study. <i>J Urol</i>. 2014;192(2):506-511. doi:10.1016/j.juro.2014.01.091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/24518765/pubmed" id="24518765" target="_blank">24518765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22471591">
<a name="22471591"></a>Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. <i>BJU Int</i>. 2012;110(7):1014‐1022. doi:10.1111/j.1464-410X.2012.11088.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/22471591/pubmed" id="22471591" target="_blank">22471591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31768615">
<a name="31768615"></a>Theriault B, Morin F, Cloutier J. Safety and efficacy of Tamsulosin as medical expulsive therapy in pregnancy. <i>World J Urol</i>. 2020;38(9):2301-2306. doi:10.1007/s00345-019-03022-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/31768615/pubmed" id="31768615" target="_blank">31768615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20642551">
<a name="20642551"></a>Tsuda Y, Tatami S, Yamamura N, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. <i>Br J Clin Pharmacol</i>. 2010;70(1):88-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/20642551/pubmed" id="20642551" target="_blank">20642551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20022041">
<a name="20022041"></a>Van Batavia JP, Combs AJ, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy. <i>J Urol</i>. 2010;183(2):724-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/20022041/pubmed" id="20022041" target="_blank">20022041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23537687">
<a name="23537687"></a>Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). <i>Eur Urol</i>. 2013;64(3):398-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/23537687/pubmed" id="23537687" target="_blank">23537687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21802124">
<a name="21802124"></a>Vicentini FC, Mazzucchi E, Brito AH, Chedid Neto EA, Danilovic A, Srougi M. Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. <i>Urology</i>. 2011;78(5):1016-1021. doi:10.1016/j.urology.2011.04.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/21802124/pubmed" id="21802124" target="_blank">21802124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19277623">
<a name="19277623"></a>Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. <i>Urol Res</i>. 2009a;37(3):147-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/19277623/pubmed" id="19277623" target="_blank">19277623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19641362">
<a name="19641362"></a>Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. <i>Urol Int</i>. 2009b;83(1):66-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/19641362/pubmed" id="19641362" target="_blank">19641362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9696967">
<a name="9696967"></a>Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. <i>Eur J Clin Pharmacol</i>. 1998;54(4):367-373. doi:10.1007/s002280050477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/9696967/pubmed" id="9696967" target="_blank">9696967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21791359">
<a name="21791359"></a>Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. <i>J Urol</i>. 2011;186(3):928-934.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/21791359/pubmed" id="21791359" target="_blank">21791359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21083640">
<a name="21083640"></a>Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic. <i>BJU Int</i>. 2011;108(2):276-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/21083640/pubmed" id="21083640" target="_blank">21083640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29137830">
<a name="29137830"></a>Ye Z, Zeng G, Yang H, et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Eur Urol.</i> 2018;73(3):385-391. doi: 10.1016/j.eururo.2017.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamsulosin-drug-information/abstract-text/29137830/pubmed" id="29137830" target="_blank">29137830</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9654 Version 467.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
